STOCK TITAN

Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) to Release Q2 2023 Financial Results on August 8, 2023. President and CEO, Scott Tarriff, and CFO, Brian Cahill, to Host Conference Call. Webcast and replay available at www.eagleus.com
Positive
  • None.
Negative
  • None.

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens.

Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

DateTuesday, August 8, 2023
Time8:30 a.m. ET
Toll free (U.S.)800-343-4136
International203-518-9814

Webcast (live and replay) www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for two weeks after the call's completion by dialing 800-839-9409 (U.S.) or 402-220-6088 (International) and entering conference call ID EGRXQ223. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc. 
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Contact:
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com


FAQ

When will Eagle Pharmaceuticals release its Q2 2023 financial results?

Eagle Pharmaceuticals will release its Q2 2023 financial results on Tuesday, August 8, 2023, before the market opens.

Who will host the conference call to discuss the Q2 2023 financial results?

President and CEO, Scott Tarriff, and CFO, Brian Cahill, will host the conference call to discuss the Q2 2023 financial results.

Where can I access the webcast and replay of the conference call?

The webcast and replay of the conference call will be available at www.eagleus.com, under the 'Investor Relations' section.

How long will the replay of the conference call be available?

A replay of the conference call will be available for two weeks after the call's completion.

Where will the webcast be archived?

The webcast will be archived for 30 days at www.eagleus.com.

EAGLE PHARMS INC

OTC:EGRX

EGRX Rankings

EGRX Latest News

EGRX Stock Data

26.56M
12.99M
12.02%
93.81%
2.71%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
WOODCLIFF LAKE